CTOs on the Move

Watermark Medical

www.watermarkmedical.com

 
Watermark Medical is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Boca Raton, FL. To find more information about Watermark Medical, please visit www.watermarkmedical.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Evanston Regional Hospital

Evanston Regional Hospital is your community healthcare provider; a 42-bed facility with complete inpatient and outpatient care. We believe in the power of people to create great care. We`re more than 50 healthcare professionals strong. We are a Joint Commission accredited facility. And we work hard every day to be a place of healing, caring and connection for patients and families in the community we call home.

Chancellor Health Trust

Chancellor Health Trust is a Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elkhart General Healthcare System

For 100 years, the highly skilled professionals of Elkhart General Hospital have been providing comprehensive medical care to Elkhart and surrounding communities.

The Regional Medical Center at Memphis

The Regional Medical Center at Memphis, commonly known as The MED, is a regional healthcare resource providing accessible, efficient, quality healthcare for individuals throughout a 5-state region within 150 miles of Memphis.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.